Solasta Ventures

What Solasta Ventures does

Solasta Ventures, Inc. is a US-incorporated venture capital firm headquartered at Prudential Tower in Boston with an additional office in San Francisco. It operates as a wholly-owned subsidiary of Aju IB Investment, one of the most established venture capital firms in South Korea, and was previously known in the U.S. as Aju IB Investment. The firm focuses on healthcare and life sciences, investing in innovative companies developing therapeutics and discovery platforms that address diseases with unmet medical needs. Its visible portfolio spans public and private biotech companies including Amphivena, Apellis, Arcellx, Arvinas, Axonis, G1 Therapeutics, Hotspot, and Kymera.

The firm's core value proposition rests on deep scientific expertise, a leadership team with more than 30 years of combined healthcare investment and drug development experience, and a Scientific Advisory Board that includes William C. Hahn, M.D., Ph.D. and Byoung Chul Cho, M.D., Ph.D. Its go-to-market leverages relationships with strategics and investigators in South Korea to bridge US-Korea synergies, sourcing deals through direct equity investment, industry conferences, and the in-house Solasta Hatchery — an informal forum that connects early-stage scientists and entrepreneurs with experienced biotech investors. The firm does not develop proprietary technology and does not sell products or services; revenue is generated through returns on portfolio investments realized via IPOs, acquisitions, or other liquidity events.

The investment mandate has historically been therapeutics-focused, but in October 2025 Solasta co-invested in the Series A of Summer Robotics, a machine-vision platform company, signaling broadening into deep tech adjacencies potentially sourced through its Korean parent network. Several high-profile portfolio exits materialized in 2025–2026, including Apellis' $5.6 billion acquisition by Biogen (announced March 2026), Gilead's $7.8 billion acquisition of Arcellx (announced February 2026), and GSK's $2.2 billion acquisition of Rapt (announced January 2026), providing validation of prior investment performance.

Name

Solasta Ventures

Legal name

Solasta Ventures, Inc.

Website

https://solasta-ventures.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Solasta Ventures is a Boston-based venture capital firm (with a San Francisco office) and wholly-owned US subsidiary of South Korean VC Aju IB Investment, investing in therapeutics and life sciences companies that address unmet medical needs and bridging US-Korea biotech deal flow.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

All Other Financial Investment Activities (52399)

akta.pro primary industry

Venture Debt Providers (FSANAAAL)

Keywords

• Venture capital
• Healthcare investing
• Life sciences
• Biotech investment
• Therapeutics funding

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Investment Returns: Solasta Ventures generates returns through equity investments in early-stage to mid-stage therapeutic companies. The firm invests in companies developing innovative treatments for diseases with unmet medical needs, seeking to transform patients' lives worldwide. Returns are realized through exits via IPOs, acquisitions, or other liquidity events.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Solasta Ventures is a venture capital firm that invests equity capital in early-stage to mid-stage therapeutic companies developing innovative treatments and discovery platforms for diseases with unmet medical needs. The firm deploys capital directly to portfolio companies, provides strategic guidance, and leverages its US-Korea network to support portfolio growth, with returns realized through exits such as IPOs and acquisitions.

Product overview

Solasta Ventures is a venture capital firm that does not offer products or services in the traditional sense. The company (formerly known as Aju IB Investment in the U.S.) is a wholly-owned subsidiary of Aju IB Investment, a leading South Korean venture capital firm. Solasta Ventures invests in innovative companies that advance the standard of care for diseases with unmet medical needs, focusing on therapeutics and discovery platforms with potential to transform patients' lives worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Venture Capital Investment in Therapeutic Companies

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• OrbiMed Advisors: Large, established healthcare-dedicated investment firm covering venture, growth, and public equities across biotech, medtech, and healthcare services. A scaled incumbent against which Solasta competes for healthcare deal flow.
• ARCH Venture Partners: One of the largest and most established biotech-focused venture capital firms, with a track record of co-founding breakthrough therapeutics companies. A scaled incumbent that competes for the same academic spinouts Solasta targets.
• Andreessen Horowitz (Bio/Health Fund): Major venture firm with a dedicated bio/health fund investing across biotech and digital health. A scaled incumbent competing for the same academic spinouts and biotech founders that Solasta targets.

Direct peers

• RA Capital Management: Healthcare-focused crossover fund investing in private and public biotech. Directly comparable to Solasta in healthcare specialization and willingness to support clinical-stage biotech.
• Atlas Venture: Boston-based early-stage biotech venture capital firm with a similar lean team structure and focus on forming and seeding therapeutic companies from academic science. Closely comparable in stage focus, geography, and approach to Solasta's core model.
• venBio: Biotech-focused venture capital firm investing in therapeutic companies across stages. Directly comparable to Solasta in therapeutic specialization and biotech-only investment focus.
• 5AM Ventures: Early-stage biotech-focused venture capital firm investing in formation-stage therapeutic companies. Directly comparable to Solasta in stage focus and biotech specialization.
• F-Prime Capital: Healthcare-focused venture capital firm (formerly Fidelity Biosciences) investing across biotech and health tech. Directly comparable as a healthcare-specialized VC with a comparable investment stage range.
• Polaris Partners: Boston-based venture firm with a significant healthcare and biotech practice focused on early-stage therapeutic companies. Comparable geography, stage focus, and biotech specialization to Solasta.

Regional players

• Korea Investment Partners: One of the largest Korean venture capital firms with significant biotech and life sciences activity. A regional peer sharing the Korean biotech ecosystem that Solasta accesses through Aju IB Investment.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments36 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solasta Ventures